Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Depreciation: 2019-2022

Historic Accumulated Depreciation for C4 Therapeutics (CCCC) over the last 1 years, with Mar 2022 value amounting to $7.2 million.

  • C4 Therapeutics' Accumulated Depreciation rose 17.77% to $7.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $7.2 million, marking a year-over-year increase of 17.77%. This contributed to the annual value of $6.9 million for FY2021, which is 22.80% up from last year.
  • C4 Therapeutics' Accumulated Depreciation amounted to $7.2 million in Q1 2022, which was up 3.59% from $6.9 million recorded in Q4 2021.
  • C4 Therapeutics' Accumulated Depreciation's 5-year high stood at $7.2 million during Q1 2022, with a 5-year trough of $4.0 million in Q4 2019.
  • Its 3-year average for Accumulated Depreciation is $6.3 million, with a median of $6.5 million in 2021.
  • Data for C4 Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 42.44% (in 2020) over the last 5 years.
  • Quarterly analysis of 4 years shows C4 Therapeutics' Accumulated Depreciation stood at $4.0 million in 2019, then spiked by 42.44% to $5.6 million in 2020, then increased by 22.80% to $6.9 million in 2021, then increased by 17.77% to $7.2 million in 2022.
  • Its last three reported values are $7.2 million in Q1 2022, $6.9 million for Q4 2021, and $6.8 million during Q3 2021.